Where is Cycuria located?

Cycuria is headquartered in Graz, Austria.

How many employees does Cycuria have?

As of Sep 30, 2026, the latest employee count at Cycuria is 9.

Is Cycuria a funded company?

Cycuria is a funded company, having raised an undisclosed amount across 2 funding rounds to date. The company's 1st funding round was a $***** Seed round.

When was the latest funding round of Cycuria?

Cycuria's latest funding was a $***** Grant (prize money) round on Apr 28, 2025, with participation from 2 investors. Its primary sector is Oncology. Globally, the Oncology sector has seen $9.51B in funding in 2026 to date.

Where does Cycuria rank among its competitors?

Cycuria ranks 59th amongst 104 active competitors, of which 34 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Orca Bio, which secured $250M in Jan, 2026.

Who are the top competitors of Cycuria?

Cycuria's top competitors include Ossium Health, Orca Bio and Rigel. Among them, Orca Bio secured the most recent funding round in January, 2026.

Cycuria - 2026 Company Profile, Funding & Competitors

Company Details

Developer of protein-based targeted therapies for hematological and solid cancers. The company engineers biologics to target leukemic cells and progenitor stem cells. The approach aims to preserve healthy blood formation and minimize systemic toxicity. The company's therapeutic strategy seeks to address unmet needs in cancer treatment.

Key Metrics

Founded Year

2024

Location

Graz, Austria

Stage

Seed

Latest Funding Round

Grant (prize money), Apr 28, 2025, $*****

Investors

FFG & 2 more

Ranked

59^th among 104 active competitors

Employee Count

9 as on Sep 30, 2026

Similar Companies

Ossium Health & 102 more

View Cycuria's full profile

Cycuria has raised funding over 2 rounds. Its latest funding round was a Grant (prize money) round on Apr 28, 2025 for $*****. 2 investors participated in its latest round. Cycuria has 3 institutional investors.

Here is the list of recent funding rounds of Cycuria:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Apr 28, 2025	7442913	Grant (prize money)	1032019	7300163	1788010	1037362

Access funding benchmarks and valuations. Sign up today!

View details of Cycuria's funding rounds and investors

Cycuria's employee count trend

Cycuria has 9 employees as of Sep 26. Here is Cycuria's employee count trend over the years:

Uncover Cycuria's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Cycuria include Ossium Health, Orca Bio and Rigel. Here is the list of Top 10 competitors of Cycuria, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Ossium Health 2016, San Francisco (United States), Series C	Developer of cell therapy products for blood cancers, tissue damage healing & radiation poisoning	$125M	Vivo Capital, CPMG & 12 others	67/100
2nd	Orca Bio 2016, Menlo Park (United States), Series F	Developer of Allogeneic cell therapy for cancer, autoimmune diseases and genetic blood disorders	$300M	Lightspeed Venture Partners, Mubadala & 11 others	65/100
3rd	Rigel 1996, San Francisco (United States), Public	Developer of drugs for hematologic disorders, cancer, and rare immune disease	-	MidCap Financial, ProQuest Investments & 6 others	64/100
4th	MaaT Pharma 2014, Lyon (France), Public	Developer of microbiome therapy for the treatment of intestinal dysbiosis diseases	$42.3M	Symbiosis, Credit Mutuel Equity & 11 others	63/100
5th	Ajax 2019, Cambridge (United States), Acquired	Developer of targeted therapies for the treatment of hematologic malignancies	$135M	EcoR1, Goldman Sachs Asset Management & 8 others	63/100
6th	Adicet Bio 2014, Menlo Park (United States), Public	Developer of immune cell therapeutic solutions for the treatment of cancer	$51M	Consensus Business Group, Samsung Venture Investment ... & 18 others	61/100
7th	Sierra Oncology 2003, Vancouver (Canada), Acquired	Developer of targeted therapies to treat cancer	$75M	Vivo Capital, Adams Street Partners & 18 others	59/100
8th	Curocell 2016, Yuseong District (South Korea), Series D	Developer of immune cell therapies	$82.4M	QUAD, Atinum Investment & 21 others	58/100
9th	Alpha-9 Theranostics 2019, Vancouver (Canada), Series B	Developer of molecules for solid and hematologic malignancies	$83.9M	Longitude Capital, Nextech Invest & 5 others	58/100
10th	ATB Therapeutics 2017, Marche en Famenne (Belgium), Series A	Developer of mAb based therapy in oncology	$56.9M	EQT, MRLV & 8 others	57/100
59th	Cycuria 2024, Graz (Austria), Seed	Developer of protein-based targeted therapies for hematological and solid cancers	-	FFG, Austria Wirtschaftsservice & 1 others	30/100